# Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer

> **NCT06478225** · NA · RECRUITING · sponsor: **RenJi Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Tumor Pancreas

## Interventions

- **DRUG:** BGT007H Cell Injection

## Key facts

- **NCT ID:** NCT06478225
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-07
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06478225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06478225, "Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06478225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*